PURPOSE: To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C → T), and the response of patients with late-stage non-small cell lung cancer (NSCLC) (n = 142) to cisplatin-based chemotherapy. METHODS: The SNP, Asn118Asn (C → T), in codon 118 of ERCC1 was detected using an AllGlo™ Probe-based real-time PCR kit. The short-term clinical outcomes were evaluated by measuring complete and partial responses (CR and PR), whereas progression-free survival (PFS) and overall survival (OS) were determined to indicate long-term outcomes. RESULTS: The allelic frequencies of the ERCC1 codon 118 were found to be 60.6% (C/C), 33.1% (C/T), and 6.3% (T/T), respectively. Overall, the CR and PR to cisplatin-based treatment were 33.1%. Notably, the response rate of patients carrying an ERCC1 118 C/C allele was more than twofold higher than that of patients with a C/T or T/T genotype (95% confidence interval (CI), 1.065-3.910, P = 0.032). Correspondingly, the long-term median PFS and OS of patients carrying the ERCC1 118 C/C allele were significantly longer than those of patients carrying a C/T or T/T allele (P < 0.01). Besides, positive correlation was observed between the differentiation status and tumor staging as well as the C/C genotype. CONCLUSIONS: Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. Moreover, by assaying this SNP in blood cells, the ERCC1 codon 118 may represent a valuable biomarker in developing individualized treatments for NSCLC patients.
PURPOSE: To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C → T), and the response of patients with late-stage non-small cell lung cancer (NSCLC) (n = 142) to cisplatin-based chemotherapy. METHODS: The SNP, Asn118Asn (C → T), in codon 118 of ERCC1 was detected using an AllGlo™ Probe-based real-time PCR kit. The short-term clinical outcomes were evaluated by measuring complete and partial responses (CR and PR), whereas progression-free survival (PFS) and overall survival (OS) were determined to indicate long-term outcomes. RESULTS: The allelic frequencies of the ERCC1 codon 118 were found to be 60.6% (C/C), 33.1% (C/T), and 6.3% (T/T), respectively. Overall, the CR and PR to cisplatin-based treatment were 33.1%. Notably, the response rate of patients carrying an ERCC1 118 C/C allele was more than twofold higher than that of patients with a C/T or T/T genotype (95% confidence interval (CI), 1.065-3.910, P = 0.032). Correspondingly, the long-term median PFS and OS of patients carrying the ERCC1 118 C/C allele were significantly longer than those of patients carrying a C/T or T/T allele (P < 0.01). Besides, positive correlation was observed between the differentiation status and tumor staging as well as the C/C genotype. CONCLUSIONS: Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. Moreover, by assaying this SNP in blood cells, the ERCC1 codon 118 may represent a valuable biomarker in developing individualized treatments for NSCLCpatients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: Puck Knipscheer; Markus Räschle; Agata Smogorzewska; Milica Enoiu; The Vinh Ho; Orlando D Schärer; Stephen J Elledge; Johannes C Walter Journal: Science Date: 2009-11-12 Impact factor: 47.728
Authors: Shenli Zhang; Iain B Tan; Nur S Sapari; Heike I Grabsch; Alicia Okines; Elizabeth C Smyth; Toru Aoyama; Lindsay C Hewitt; Imran Inam; Dan Bottomley; Matthew Nankivell; Sally P Stenning; David Cunningham; Andrew Wotherspoon; Akira Tsuburaya; Takaki Yoshikawa; Richie Soong; Patrick Tan Journal: J Mol Diagn Date: 2015-03-04 Impact factor: 5.568
Authors: L Galluzzi; I Vitale; J Michels; C Brenner; G Szabadkai; A Harel-Bellan; M Castedo; G Kroemer Journal: Cell Death Dis Date: 2014-05-29 Impact factor: 8.469